Overall, our data indicate that the measurement of the expression of miR-21 at baseline or in residual cancer after neoadjuvant therapy may be used to understand the likelihood of therapeutic response and to select patients harboring HER2-positive, drug-resistant tumors who may benefit from novel pharmacological agents. The gene discussed is ERBB2; the disease is cancer.